NCT07197554View on ClinicalTrials.gov

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Advanced Solid TumorsEwing SarcomaHepatocellular Carcinoma (HCC)Biliary Tract Cancer (BTC)
Interventions
DRUG

ST-01156

ST-01156 is an orally administered degrader of RBM39, a protein frequently upregulated in cancer

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

77030

The University of Texas MD Anderson Cancer Center, Houston

91010

The City of Hope National Medical Center, Duarte

92263

Hoag Memorial Hospital, Newport Beach

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

SEED Therapeutics, Inc.

INDUSTRY